R EFERÊNCIAS
A
A
n
n
d
d
r
r
e
e
z
z
z
z
a
a
C
C
a
a
m
m
a
a
r
r
i
i
n
n
h
h
a
a
N
N
a
a
p
p
o
o
l
l
i
i
t
t
a
a
n
n
o
o
B
B
a
a
r
r
c
c
e
e
l
l
o
o
s
s
144
Sehgal VN, Luthra A, Bajaj P. Epidermodysplasia verruciformis: 14 member
of a pedigree with an intriguing squamous cell carcinoma transformation. Int
J Dermatol. 2002;41(8):500-3.
Silva CS, Ramos RO, Pires MC, Sittart JA. Epidermodisplasia verruciforme:
tratamento combinado com aciteretin e interferon alfa-2a. An Bras Dermatol.
2006; 81(6):595-7.
Shamanin V, zur Hausen H, Lavergne D, Proby CM, Leigh IM, Neumann C,
Hamm H, Goos M, Haustein UF, Jung EG, Plewig G, Wolff H, de Villiers EM.
Human papillomavirus infection in nonmelanoma skin cancers from renal
transplant recipients an noimmunosupressed patients. J Natl Cancer Inst.
1996; 88(12):802-11.
Smack DP, Korge BP, James WD. Keratin and keratinization. J Am Acad
Dermatol. 1994;30(1):85-102.
Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol.
2003;4(5):347-67.
Smoller BR, Krueger J, McNutt NS, Hsu A. “Activated” keratinocyte
phenotype is unifying feature in conditions which predispose to squamous
cell carcinoma of the skin. Mod Pathol. 1990;3(2): 171-5.
Staquet MJ, Viac J, Thivolet J. Keratin polypeptide modifications induced by
human papillomaviruses (HPV). Arch Dermatol Res. 1981;271(1):83-90.
Stark S, Petridis AK, Ghim SJ, Jenson AB, Bouwes Bavinck JN, Gross G,
Stockfleth E, Fuchs PG, Pfister H. Prevalence of antibodies against virus-like
particles of Epidermodysplasia verruciformis-associated HPV 8 in patients
at risk of skin cancer. J Invest Dermatol. 1998;111(4):696-701.
Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM,
Maltais L, Omary MB, Parry DA, Rogers MA, Wright MW. New consensus
nomenclature for mammalian keratins. J Cell Biol. 2006;174(2):169-74.